Ophthalmology 공개
[search 0]

Download the App!

show episodes
 
Open. Outspoken. It's Ophthalmology off the Grid—an honest look at controversial topics in the field. Host Gary Wörtz, MD, invites a range of experts to guide listeners through their areas of expertise, inserting thought-provoking questions along the way. From disruptive treatments and technologies to tried-and-true ophthalmic practices, Ophthalmology Off the Grid lends a curious perspective to topics new and old for an honest look at ophthalmology today.
 
MedEdTalks Ophthalmology is a continuing medical education podcast for physicians to allow them to learn while on the go and obtain CME credits. This show will focus in on ophthalmology topics, such as nAMD and Diabetic Retinopathy and includes interviews with Dr. Rishi Singh from the Cole Eye Institute, Dr. Andrew Moshfeghi from the USC Roski Eye Institute, Dr. Dilsher Dhoot from California Retina Consultants, Dr. Theodore Leng from Byers Eye Institute at Stanford, Dr. Nathan Steinle from C ...
 
Journal of Neuro-Ophthalmology keeps pace with important advances in all spheres of the neurologic and ophthalmologic sciences. Clinicians and researchers worldwide report on recent developments in diagnosing and treating ophthalmologic, neurologic, endocrine, inflammatory, and neoplastic conditions affecting the oculomotor and visual systems. The Journal publishes original, peer-reviewed articles on both clinical and basic aspects of neuro-ophthalmology. Other regular features include revie ...
 
Loading …
show series
 
In this episode, Blake Williamson, MD, MPH, is joined by cohost Ashley Brissette, MD, MSc, FRCSC, and guest Will Flanary, MD—famously known as Dr. Glaucomflecken on Twitter and TikTok—to discuss the value of being a physician with a sense of humor. They discuss how humanity can break down barriers between physicians and patients, and the fine line …
 
In this episode of the Survive & Thrive series, Gary Wörtz, MD, is joined by Cherie Fathy, MD, and David Felsted, DO, and special guest Bilal Ahmed, BS, a fourth-year medical student at the University of Toledo School of Medicine. They each share their experiences applying for ophthalmology residency, and Bilal tells his story about finding ophthal…
 
In this episode of the Survive & Thrive series, Gary Wörtz, MD, is joined by Nandini Venkateswaran, MD; Dagny Zhu, MD; Cherie Fathy, MD; and David Felsted, DO, to talk about the one challenge that every young doctor inevitably faces: the job hunt. They discuss what to consider when choosing a job, how to handle contract negotiations, and navigating…
 
In this special Thanksgiving episode of Ophthalmology Off the Grid, host Blake Williamson, MD, MPH, invites his colleagues to join him in expressing their gratitude. Hear from Dr. Williamson; Richard L. Lindstrom, MD; Evan Schoenberg, MD; Iqbal Ike K. Ahmed, MD, FRCSC; and Zaina Al-Mohtaseb, MD, on what has them feeling thankful in these particular…
 
In this episode of the Survive & Thrive series, Gary Wörtz, MD, is joined by Nandini Venkateswaran, MD; Dagny Zhu, MD; and guest Preeya Gupta, MD, to talk about one of the big decisions faced by young ophthalmologists: private practice or academia? They weigh the pros and cons of each career path and share their own experiences in navigating this c…
 
In this podcast of the Survive & Thrive series, Gary Wörtz, MD, is joined by Cherie Fathy, MD; Nandini Venkateswaran, MD; David Felsted, DO; Dagny Zhu, MD; and guest Uday Devgan, MD, FACS, to talk about performing surgery alone for the first time. Drs. Venkateswaran and Felsted share their recent experiences as first-time solo surgeons, and the oth…
 
Cohosts Gary Wörtz, MD, and Blake Williamson, MD, MPH, invite cornea specialist Ed Holland, MD, of the Cincinnati Eye Institute to discuss his career-long passion for treating patients with limbal stem cell deficiency. Dr. Holland shares how this passion led to the development of his Cincinnati Protocol and the creation of the Holland Foundation fo…
 
In this webcast of the Survive & Thrive series, moderators Gary Wörtz, MD, and Lisa Nijm, MD, JD, are joined by Cherie Fathy, MD; Nandini Venkateswaran, MD; David Felsted, DO; and Ashley Brissette, MD, MSc, FRCSC, for a conversation about gender equality in ophthalmology. They touch on the barriers faced by women in ophthalmology, the importance of…
 
In this episode, cohosts Gary Wörtz, MD, and Blake Williamson, MD, MPH, are joined by ophthalmology’s favorite comedian, Dr. Glaucomflecken. Dr. G talks about how comedy started as his creative outlet and led to him becoming the comedic voice of medicine on Twitter. He also shares how he has used humor to help him cope with personal adversity.…
 
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remai…
 
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remai…
 
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remai…
 
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remai…
 
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment regimens have provided significant improvements to long-term visual outcomes in neovascular age-related macular degeneration (nAMD). However, some patients do not receive an optimal response with current anti-VEGF therapies, while poor adherence due to treatment burden remai…
 
Cohost Blake Williamson, MD, MPH, invites Raymond Stein, MD, from Bochner Eye Institute in Toronto for a conversation about the PanOptix, a presbyopia-correcting IOL that was first approved by the FDA last year. Dr. Stein draws on his extensive experience and shares surgical pearls for US-based surgeons who are acclimating to this new technology.…
 
Cohost Blake Williamson, MD, MPH, invites Raymond Stein, MD, from Bochner Eye Institute in Toronto for a conversation about the PanOptix, a presbyopia-correcting IOL that was first approved by the FDA last year. Dr. Stein draws on his extensive experience and shares surgical pearls for US-based surgeons who are acclimating to this new technology.…
 
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patie…
 
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patie…
 
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patie…
 
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patie…
 
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patie…
 
The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patie…
 
Loading …

빠른 참조 가이드

Google login Twitter login Classic login